UB Paderborn / Katalog / Suche / in CDI

Ubrogepant: Mechanism of action, clinical and translational science

Clinical and translational science, 2024-01, Vol.17 (1), p.e13675-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

S535 An Open-Label Comparison Study of Eluxadoline in Participants with Irritable Bowel Syndrome with Diarrhea Who Have Evidence of Bile Acid Malabsorption

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S243-S244

2021

Link zum Volltext

Verfügbarkeit prüfen

Atogepant: Mechanism of action, clinical and translational science

Clinical and translational science, 2024-01, Vol.17 (1), p.e13707-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials

The American journal of gastroenterology, 2023-05, Vol.118 (5), p.872-879

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

The American journal of gastroenterology, 2021-02, Vol.116 (2), p.354-361

2021

Link zum Volltext

Verfügbarkeit prüfen

S529 Linaclotide Improves Symptoms of Irritable Bowel Syndrome With Constipation, Irrespective of Severity and Age: A Post-Hoc Analysis of Pooled Trials

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S240-S240

2021

Link zum Volltext

Verfügbarkeit prüfen

S510 Time to Relief of Key Abdominal and Bowel Symptoms of Irritable Bowel Syndrome with Constipation: A Post-Hoc Analysis of Randomized Controlled Trials of Linaclotide

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S228-S228

2021

Link zum Volltext

Verfügbarkeit prüfen

Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers

Journal of clinical oncology, 2009-03, Vol.27 (8), p.1220-1226

2009

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the pharmacokinetic interaction and safety of ubrogepant coadministered with acetaminophen or nonsteroidal anti-inflammatory drugs: A randomized trial

Cephalalgia reports, 2020, Vol.3, p.251581632092118

2020

Link zum Volltext

Verfügbarkeit prüfen

Influence of CYP3A4 Induction/Inhibition on the Pharmacokinetics of Vilazodone in Healthy Subjects

Clinical therapeutics, 2014-11, Vol.36 (11), p.1638-1649

2014

Link zum Volltext

Verfügbarkeit prüfen

Effects of CYP3A4 and P-glycoprotein inhibition or induction on the pharmacokinetics of ubrogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crossover trials

Cephalalgia reports, 2021, Vol.4, p.251581632110373

2021

Link zum Volltext

Verfügbarkeit prüfen

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults

Clinical and translational science, 2021-03, Vol.14 (2), p.599-605

2021

Link zum Volltext

Verfügbarkeit prüfen

A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance

Clinical and translational science, 2022-01, Vol.15 (1), p.255-266

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic and pharmacodynamic assessments of atogepant in healthy male adults: Results from phase 1 studies

Cephalalgia reports, 2023-01, Vol.6

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Ubrogepant in Healthy Japanese and White Adults

Clinical pharmacology in drug development, 2024-06, Vol.13 (6), p.688-695

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design

Clinical cancer research, 2005-09, Vol.11 (17), p.6233-6239

2005

Link zum Volltext

Verfügbarkeit prüfen

Single‐dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal Impairment

Clinical pharmacology in drug development, 2023-02, Vol.12 (2), p.132-140

2023

Link zum Volltext

Verfügbarkeit prüfen

Single‐Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial

Clinical pharmacology in drug development, 2022-07, Vol.11 (7), p.857-864

2022

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered With Esomeprazole Magnesium

Clinical pharmacology in drug development, 2022-02, Vol.11 (2), p.270-277

2022

Link zum Volltext

Verfügbarkeit prüfen

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

Clinical cancer research, 2013-02, Vol.19 (4), p.909-919

2013

Link zum Volltext

Verfügbarkeit prüfen

Lecithin vesicles for topical delivery of diclofenac

European journal of pharmaceutics and biopharmaceutics, 2003-11, Vol.56 (3), p.389-392

2003

Link zum Volltext

Verfügbarkeit prüfen

Correlation between the systemic clearance of drugs and their food effects in humans

Drug development and industrial pharmacy, 2011-11, Vol.37 (11), p.1311-1317

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Safety of Atogepant Co-administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study

Clinical pharmacology in drug development, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

Iontophoresis of lecithin vesicles of cyclosporin A

International journal of pharmaceutics, 2004-04, Vol.274 (1), p.185-190

2004

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial

Clinical drug investigation, 2021-06, Vol.41 (6), p.557-567

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Ubrogepant: Mechanism of action, clinical and translational science

S535 An Open-Label Comparison Study of Eluxadoline in Participants with Irritable Bowel Syndrome with Diarrhea Who Have Evidence of Bile Acid Malabsorption

Atogepant: Mechanism of action, clinical and translational science

Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials

Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

S529 Linaclotide Improves Symptoms of Irritable Bowel Syndrome With Constipation, Irrespective of Severity and Age: A Post-Hoc Analysis of Pooled Trials

S510 Time to Relief of Key Abdominal and Bowel Symptoms of Irritable Bowel Syndrome with Constipation: A Post-Hoc Analysis of Randomized Controlled Trials of Linaclotide

Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers

Evaluation of the pharmacokinetic interaction and safety of ubrogepant coadministered with acetaminophen or nonsteroidal anti-inflammatory drugs: A randomized trial

Influence of CYP3A4 Induction/Inhibition on the Pharmacokinetics of Vilazodone in Healthy Subjects

Effects of CYP3A4 and P-glycoprotein inhibition or induction on the pharmacokinetics of ubrogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crossover trials

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults

A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance

Pharmacokinetic and pharmacodynamic assessments of atogepant in healthy male adults: Results from phase 1 studies

Pharmacokinetics of Ubrogepant in Healthy Japanese and White Adults

Phase I Clinical Trial of BMS-247550, A Derivative of Epothilone B, Using Accelerated Titration 2B Design

Single‐dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal Impairment

Single‐Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial

Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered With Esomeprazole Magnesium

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

Lecithin vesicles for topical delivery of diclofenac

Correlation between the systemic clearance of drugs and their food effects in humans

Pharmacokinetics and Safety of Atogepant Co-administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study

Iontophoresis of lecithin vesicles of cyclosporin A

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial

Suchergebnisse filtern